Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has transformed hematological cancer treatment.
• Solid tumor treatment with CAR-T cells faces significant hurdles including immunosuppression, heterogeneity, and poor T cell persistence.

Purpose of the Study:

• To review challenges in applying CAR-T cell therapy to solid tumors.
• To evaluate clinical outcomes of current CAR constructs.
• To highlight novel strategies for enhancing CAR-T cell efficacy in solid tumors.

Main Methods:

• Examination of barriers to CAR-T cell efficacy in solid tumors.
• Evaluation of clinical trial data for conventional CAR constructs.
• Review of innovative next-generation CAR-T cell strategies.

Main Results:

• Second- and third-generation CAR-T cells show limited efficacy in solid tumors.
• Next-generation strategies like cytokine-armored CAR-T cells, logic-gated systems, and localized delivery show potential.
• Advanced approaches include dominant-negative receptors (e.g., TGFβRII) and bispecific T cell engagers (BiTEs).

Conclusions:

• Overcoming the immunosuppressive tumor microenvironment is crucial for CAR-T cell success.
• Innovative CAR-T cell designs are essential to address antigen escape and improve persistence.
• Next-generation CAR-T cell therapies offer promising avenues for treating solid tumors.